Pfizer will pay $330 million upfront for ex-China rights to three preclinical in vivo CAR-T programs from Starna Therapeutics. The agreement includes up to $2.3 billion in milestones plus royalties, and Pfizer plans to lead development outside Greater China.
News
Diagnostics
Innovation
Research
The Research category covers the latest medical studies, breakthroughs, and scientific advancements shaping the future of healthcare.

